Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
13 September 2018
GenSight Biologics provides an update on the clinical and regulatory pathways for GS010
25 July 2018
GenSight Biologics Reports Interim Financial Results for the First Half of 2018
20 June 2018
Key Opinion Leaders highlight GS010 efficacy and patient benefits in discussion of findings from REVERSE Phase III clinical trial
12 June 2018
GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON)
26 April 2018
GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO
25 April 2018
GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010
03 April 2018
GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)
28 February 2018
GenSight Biologics Reports Full Year 2017 Financial Results
20 February 2018
GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology
25 January 2018
GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update
View previous 9 articles
1
…
14
15
16
17
18
19
20
21
22
23
24
View next 9 articles
Go back to the page of the page